Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma

Abstract

Background This study investigated the expression and biological function of JAB1 in esophageal squamous cell carcinoma (ESCC). Methods The expression of JAB1 in ESCC tissues and cells was measured using reverse transcriptase‐polymerase chain reaction (RT‐PCR), immunohistochemistry (IHC), and western blot analysis. Kaplan‐Meier survival analysis was performed to explore the effect of JAB1 expression on the prognosis of ESCC patients. Furthermore, experiments were conducted in vivo and in vitro to determine the effect of JAB1 expression on the malignant behavior of ESCC cells. Results Compared with adjacent tissues, JAB1 was highly overexpressed in cancer tissues (P = 0.01). Univariate and multivariate analyses of clinical data indicated that patients with JAB1 overexpression had a worse prognosis (P = 0.001 and P = 0.049, respectively). Cell function experiments and tumorigenesis experiments in nude mice showed that the upregulation of JAB1 might promote malignant behavior, and vice versa. Conclusions Overexpression of JAB1 promoted the proliferation, migration, and invasion of ESCC cells, and was significantly associated with poor prognosis of ESCC patients. Therefore, JAB1 could be considered as a promising prognostic factor and a possible target for the specific therapy of ESCC. Key points In this study, we found that JAB1 was highly overexpressed in cancer tissues, which could influence the malignant behavior of ESCC cells, and was significantly associated with poor prognosis of ESCC patients.

<p>Expression of Integrin β6 and HAX-1 Correlates with Aggressive Features and Poor Prognosis in Esophageal Squamous Cell Carcinoma</p>

“…Metastasis may occur at the early stage and initial diagnosis of ESCC, and along with the high incidence of postoperational recurrence, there are poor outcomes for patients with ESCC. Although pTNM stage classification is mostly utilized for survival reference, there is a great interest to discover alternative molecular biomarkers to supplement the pTNM staging system for early diagnosis and prognostic evaluation, 18 which will facilitate the development of target therapy to treat highly lethal malignancy, such as ESCC. The development and progression of ESCC is a complicated process in which cancer cell adhesion, proliferation and motility mediated by integrins are involved by connecting the cytoskeleton to ECM.…”

Corrigendum

“…

In Shen et al 1 the following errors were published on pages 979 and 981. There were errors with the images and with the grouping of the images for Figures 2 and 4.

…”